Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2020

01-09-2020 | Heart Failure | Research Letter

Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis

Authors: Mei Qiu, Shu-Yan Liu, Jin-Song Gu, Kai-Kai Li, Ling-Lin Li, Liang-Liang Ding

Published in: Endocrine | Issue 3/2020

Login to get access

Excerpt

Large cardiovascular (CV) outcome trials demonstrated sodium glucose cotransporter 2 inhibitors (SGLT2is) could significantly reduce cardiorenal events in type 2 diabetic adults. However, the effects of SGLT2is on cardiorenal endpoints in many diabetic subpopulations are undefined because of the following two main reasons. …
Appendix
Available only for authorised users
Literature
1.
S.D. Wiviott, I. Raz, M.P. Bonaca et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380(4), 347–357 (2019)CrossRef
2.
B. Neal, V. Perkovic, K.W. Mahaffey et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377(7), 644–657 (2017)CrossRef
3.
B. Zinman, C. Wanner, J.M. Lachin et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128 (2015)CrossRef
4.
V. Perkovic, M.J. Jardine, B. Neal et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380(24), 2295–2306 (2019)CrossRef
5.
D. Fitchett, B. Zinman, C. Wanner et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the empa-reg outcome(r) trial. Eur. Heart J. 37(19), 1526–1534 (2016)CrossRef
6.
C. Wanner, S.E. Inzucchi, J.M. Lachin et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375(4), 323–334 (2016)CrossRef
7.
K. Radholm, G. Figtree, V. Perkovic et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 138(5), 458–468 (2018)CrossRef
8.
V. Perkovic, D. de Zeeuw, K.W. Mahaffey et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the canvas program randomised clinical trials. Lancet Diabetes Endocrinol. 6(9), 691–704 (2018)CrossRef
9.
O. Mosenzon, S.D. Wiviott, A. Cahn et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the declare-timi 58 randomised trial. Lancet Diabetes Endocrinol. 7(8), 606–617 (2019)CrossRef
10.
K.W. Mahaffey, M.J. Jardine, S. Bompoint et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140(9), 739–750 (2019)CrossRef
11.
C.P. Cannon, V. Perkovic, R. Agarwal et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline hba1c, including those with hba1c <7%: results from the credence trial. Circulation 141(5), 407–410 (2020)CrossRef
12.
J. McMurray, S.D. Solomon, S.E. Inzucchi et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995–2008 (2019)CrossRef
13.
T.A. Zelniker, S.D. Wiviott, I. Raz et al. Sglt2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019)CrossRef
14.
B.L. Neuen, T. Young, H. Heerspink et al. Sglt2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol, 7(11), 845–854 (2019)CrossRef
15.
C. Arnott, Q. Li, A. Kang et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J. Am. Heart Assoc. 9(3), e14908 (2020)CrossRef
16.
T. Toyama, B.L. Neuen, M. Jun et al. Effect of sglt2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes. Obes. Metab. 21(5), 1237–1250 (2019)CrossRef
17.
S.E. Inzucchi, D. Fitchett, D. Jurišić-Eržen et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes Obes. Metab. 22(4), 631–639 (2020)CrossRef
18.
T. Ohkuma, L. Van Gaal, W. Shaw et al. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the canvas program. Diabetes Obes. Metab. 22(4), 530–539 (2020)CrossRef
19.
J.B. Buse, D.J. Wexler, A. Tsapas et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ada) and the european association for the study of diabetes (easd). Diabetes Care 43(2), 487–493 (2020)CrossRef
Metadata
Title
Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
Authors
Mei Qiu
Shu-Yan Liu
Jin-Song Gu
Kai-Kai Li
Ling-Lin Li
Liang-Liang Ding
Publication date
01-09-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02359-5

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue

Original Article

Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase

Original Article

Differential effects of metformin on reductive activity and energy production in pituitary tumor cells compared to myogenic precursors

Viewpoint

Mechanism of higher risk for COVID-19 in diabetes: a mask to lift

Endocrine Methods and Techniques

Treating thyroid nodules by radiofrequency: is the delivered energy correlated with the volume reduction rate? A pilot study

Original Article

Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness

Original Article

Combined therapy with GnRH analogue and growth hormone increases adult height in children with short stature and normal pubertal onset
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits